

Contents

1	Introduction	1
1.1	Sequential Experimentation in Translational Medical Research	1
1.2	Sequential Analysis: From Weapons Testing to Confirmatory Clinical Trials	2
1.3	Adaptation and Sequential Optimization	5
1.4	Two Time Scales and Time-Sequential Survival Analysis	6
1.5	Bayesian and Frequentist Approaches and Associated Software	7
2	Nonlinear Regression, Experimental Design, and Phase I Clinical Trials	11
2.1	Nonlinear Regression Models	12
2.1.1	Nonlinear Least Squares	12
2.1.2	Nonlinear Mixed Effects Models	13
2.2	Pharmacokinetics and Pharmacodynamics	16
2.3	Theory of Optimal Design	18
2.3.1	Optimal Design Theory in Linear Regression Models	19
2.3.2	Elfving's Method for c -Optimal Design	20
2.3.3	Extension to Nonlinear Models	22
2.4	Phase I Clinical Trials for Relatively Benign Drugs	23
2.5	Early Phase Clinical Trials for Cytotoxic Cancer Treatments	24
2.5.1	Up-and-Down and Related Designs	24
2.5.2	Model-Based Designs	28
2.6	Supplements and Problems	29
3	Sequential Testing Theory and Stochastic Optimization Over Time	37
3.1	Likelihood Ratio Statistics and Likelihood Ratio Identity	37
3.2	Wald's SPRT and Its Error Probabilities	38
3.3	Wald's Equation and Lower Bounds of Wald and Hoeffding	39
3.4	Lorden's 2-SPRT and Sequential GLR Tests	41
3.5	Modifications for Group Sequential Testing	43

3.6	Optimality of SPRT and Dynamic Programming	45
3.6.1	Dynamic Programming: Finite-Horizon Case	45
3.6.2	Infinite-Horizon Dynamic Programming	46
3.6.3	Bayes Sequential Tests of Simple Null Versus Simple Alternative	47
3.6.4	Auxiliary Bayes Problem and Optimality of the SPRT	50
3.7	Approximations to Bayes Sequential Tests and Operating Characteristics	51
3.7.1	Derivation of Lorden's 2-SPRT as an Approximate Bayes Rule	51
3.7.2	Approximation of Bayes Sequential Tests of One-Sided Hypotheses in an Exponential Family by Sequential GLR Tests	52
3.7.3	Laplace's Asymptotic Formula and Approximations to Operating Characteristics	56
3.8	ADP and Applications to Phase I Cancer Trial Designs	60
3.8.1	A Stochastic Optimization Problem Related to the Treatment Versus Experimentation Dilemma	60
3.8.2	Some ADP Methods	63
3.8.3	Hybrid Designs Derived by ADP	66
3.8.4	A Two-Stage Modification	70
3.9	Supplements and Problems	73
4	Group Sequential Design of Phase II and III Trials	77
4.1	Group Sequential Tests for a Normal Mean	78
4.1.1	The Pocock, O'Brien–Fleming, and Wang–Tsiatis Group Sequential Boundaries	78
4.1.2	One-Sided Group Sequential Tests: Power Family and Triangular Tests	78
4.1.3	The Lan–DeMets Error Spending Approach	80
4.2	Group Sequential Generalized Likelihood Ratio Tests with Modified Haybittle–Peto Boundaries	80
4.2.1	Maximum Sample Size and the Alternative Implied by It	81
4.2.2	Group Sequential GLR Tests with Nearly Optimal Power and Expected Sample Size	81
4.2.3	Two-Sided Tests with or Without Futility Boundaries	84
4.2.4	Extensions to Multiparameter and Multiarmed Problems	85
4.3	Implementation and Computational Methods	86
4.3.1	Asymptotic Normality and Recursive Numerical Integration	86
4.3.2	Monte Carlo and the Bootstrap for Sequential GLR Statistics	87
4.3.3	Design, Interim Analysis, and Nonparametric Extensions....	87

4.4	Comparison of Group Sequential Tests	90
4.4.1	One-Sided Tests	90
4.4.2	Two-Sided Tests Without Futility Boundaries	91
4.4.3	Unequal Group Sizes That Are Not Prespecified	93
4.5	Supplements and Problems	95
5	Sequential Methods for Vaccine Safety Evaluation and Surveillance in Public Health	101
5.1	Vaccine Safety Evaluation	101
5.1.1	Design Considerations for Clinical Trials to Test Vaccine Safety	102
5.1.2	Application of SPRT and Other Sequential Tests	103
5.2	Sequential GLR Tests in Prelicensure Randomized Clinical Trials	106
5.2.1	An Exponential Family Representation of Sequential GLR Tests	106
5.2.2	Implementation and Example	107
5.2.3	Discussion	109
5.3	The Rotavirus Efficacy and Safety Trial (REST)	109
5.4	Post-marketing Surveillance of Drug Safety	111
5.5	Sequential Change-Point Detection Methods for Pharmacovigilance and Public Health Surveillance	113
5.5.1	Sequential Change-Point Detection Methodology: An Overview	113
5.5.2	Sequential Detection in Public Health Surveillance	119
5.5.3	A Hybrid of Sequential Testing and Detection for Pharmacovigilance	119
5.6	Supplements and Problems	120
6	Time-Sequential Design of Clinical Trials with Failure-Time Endpoints	123
6.1	An Overview of Survival Analysis	123
6.1.1	Nelson–Aalen and Kaplan–Meier Estimators	124
6.1.2	Regression Models for Hazard Functions with Covariates ..	126
6.1.3	Rank Tests Based on Censored Survival Data	128
6.2	The Beta-Blocker Heart Attack Trial (BHAT)	128
6.2.1	Trial Design	128
6.2.2	Trial Execution and Interim Analysis by DSMB	129
6.2.3	Stochastic Curtailment	130
6.3	Terminal Analyses of BHAT Data	131
6.4	Developments in Group Sequential Methods Motivated by BHAT	133
6.4.1	The Lan–DeMets Error-Spending Approach	133
6.4.2	Two Time Scales and Haybittle-Type Boundaries	133
6.4.3	Conditional and Predictive Power	135

6.5	Randomized Clinical Trials with Failure-Time Endpoints and Interim Analyses	136
6.5.1	Time-Sequential Censored Rank Statistics and Their Asymptotic Distributions	136
6.5.2	Modified Haybittle–Peto Tests, Power, and Expected Savings	139
6.6	Appendix: Martingale Theory and Applications to Sequential/Survival Analysis	142
6.6.1	Optional Stopping Theorem	142
6.6.2	Predictable Variation and Stochastic Integrals	144
6.6.3	Rebolledo’s CLT	145
6.6.4	Counting Processes and Applications to Survival Analysis ..	146
6.6.5	Application to Time-Sequential Censored Rank Statistics ...	147
6.7	Supplements and Problems	148
7	Confidence Intervals and p-Values	153
7.1	Inference Following a Sequential Trial: Some Developments	154
7.1.1	Naïve Confidence Intervals, Anscombe’s Theorem, and Bayesian Methods	154
7.1.2	Exact Confidence Intervals in the Normal Case	155
7.1.3	Siegmund’s Ordering and Group Sequential Trials with Random Group Sizes	156
7.1.4	Bias Correction for A Modified Pivot	157
7.1.5	Bivariate Normal Outcomes	157
7.1.6	Extensions Beyond the Normal Cases	159
7.2	A Hybrid Resampling Approach	159
7.2.1	A General Formulation of Exact, Bootstrap, and Hybrid Resampling Methods	159
7.2.2	Hybrid Resampling Confidence Intervals for Population Means Following Group Sequential Tests Based on Sample Means	161
7.2.3	A Comparative Study	162
7.3	A General Ordering Scheme and p -Values	163
7.3.1	Total Ordering of Sample Space for p -Values	163
7.3.2	Bootstrap Methods for p -Values and Hybrid Resampling ...	165
7.4	Hybrid Resampling Approach for Secondary Endpoints	166
7.4.1	Bivariate Mean Vectors	166
7.4.2	Bivariate Nonparametric Functionals	167
7.5	Applications to Time-Sequential Survival Trials	169
7.5.1	Implementation of the Hybrid Resampling Approach	170
7.5.2	Tests on Secondary Parameters in the Cox Model	171
7.6	Simulation Studies	174
7.6.1	Confidence Intervals for Primary Endpoint of Hazard Rate	174
7.6.2	Test for Secondary Endpoint in Cox Model	177
7.7	Supplements and Problems	178

8 Adaptive Design of Confirmatory Trials	187
8.1 Internal Pilot, Midcourse Sample Size Re-estimation and Trial Extensions	189
8.1.1 Stein's Two-Stage Procedure, with the First Stage to Estimate the Variance as an Internal Pilot	189
8.1.2 Midcourse Sample Size Re-estimation	190
8.1.3 Midcourse Modification of the Maximum Sample Size in a Group Sequential Trial	192
8.1.4 Optimal Adaptive Group Sequential Designs via Dynamic Programming	193
8.2 Efficient Adaptive Design and GLR Tests	193
8.2.1 An Adaptive 3-Stage GLR Test	193
8.2.2 Midcourse Modification of Maximum Sample Size	195
8.2.3 Asymptotic Theory	196
8.2.4 Implementation via Normal Approximation or Monte Carlo	198
8.3 Comparison of Adaptive Designs	200
8.3.1 Normal Mean with Known Variance	200
8.3.2 Difference of Means with Unknown Variances	205
8.3.3 Comparison of Tests Allowing Midcourse Modification of Maximum Sample Size	207
8.3.4 Coronary Intervention Study	210
8.4 Adaptive Choice Between Superiority and Non-inferiority Objectives via a Flexible Group Sequential Design	213
8.4.1 Adaptation and Group Sequential Tests of H_0 or H'_0 When $M' \leq M$	214
8.4.2 Binary Responses and a Comparative Study	216
8.4.3 Adaptive Choice Between One Superiority and Two Non-inferiority Trials	219
8.4.4 Discussion	222
8.5 Supplements and Problems	222
References	225
Index	235

Sequential Experimentation in Clinical Trials
Design and Analysis

Bartroff, J.; Lai, T.L.; Shih, M.-C.

2013, XVI, 240 p.,

ISBN: 978-1-4614-6114-2